A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2013
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 03 May 2013 The Celgene ID for this trial (CC5013-CLL001) is also in another profile (700202091). Have left it in both profiles for now as it is not clear which one is correct.
- 18 Jan 2011 Official Title amended as reported by ClinicalTrials.gov.
- 18 Jan 2011 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.